Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI

被引：0
|
作者：
Wang, J. [1 ]
Wang, Y. [2 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Thorac Oncol, Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32P
引用
收藏
页码：S58 / S59
页数：2
相关论文
共 50 条
  • [1] The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
    Wang, Zhi
    Zhang, Lingling
    Xu, Wenwen
    Li, Jie
    Liu, Yi
    Zeng, Xiaozhu
    Zhong, Maoxi
    Zhu, Yuxi
    JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 649 - 667
  • [2] Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
    Lee, Po-Hsin
    Huang, Yen-Hsiang
    Lin, Ho
    Hsu, Kuo-Hsuan
    Chen, Kun-Chieh
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    MEDICINA-LITHUANIA, 2022, 58 (07):
  • [3] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [4] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [5] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [6] Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Tsai, Meen-Hsin
    Yu, Sung-Liang
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 603 - 610
  • [7] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [8] Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.
    Wang, Shuhang
    Wang, Jie
    Bai, Hua
    An, Tongtong
    Zhao, Jun
    Wang, Zhijie
    Duan, Jianchun
    Zhuo, Minglei
    Wang, Yuyan
    Wu, Meina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
    Ning Lou
    Ruyun Gao
    Yuankai Shi
    Xiaohong Han
    Scientific Data, 11 (1)
  • [10] Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
    Yang, Zhengyu
    Chen, Ya
    Wang, Yanan
    Wang, Shuyuan
    Hu, Minjuan
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
12345